Skip to main content
Terug
TERN logo

Terns Pharmaceuticals, Inc.

Datakwaliteit: 100%
Overbought
TERN
NASDAQ Healthcare Biotechnology
€ 50,00
▲ € 0,39 (0,79%)
Marktkapitalisatie: 4,50B
Dagbereik
€ 48,14 € 50,37
52-Weeksbereik
€ 1,87 € 50,37
Volume
2.422.504
50D / 200D Gem.
€ 39,67 / € 20,49
Vorige Slotkoers
€ 49,61

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -50,7 0,3
P/B 13,0 2,9
ROE % -29,6 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 55,67 +11.3%
Low: € 35,00 High: € 70,00
Forward WPA
-€ 1,18
Omzet Sch.
960000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 -€ 1,63
-€ 1,63 – -€ 1,63
41 M 2
FY2028 -€ 1,77
-€ 2,32 – -€ 1,18
7,9 M 7
FY2027 -€ 1,42
-€ 1,75 – -€ 0,93
5,8 M 8

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -70,06M
PEG of 0,42 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-29,56%
ROIC-22,00%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio23,14
Interest Coverage0,00

Waardering

P/E Ratio
-50,69
P/B Ratio13,02
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -88,85M
ROE -29,56% ROA -24,41%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -70,06M
ROIC -22,00% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 23,14
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -50,69 P/B Ratio 13,02
P/S Ratio N/A PEG Ratio 0,42
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 4,50B Enterprise Value 4,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 0,0 0,0 0,0 1,00M 0,0
Net Income -88,85M -90,21M -60,35M -50,16M -29,35M
EPS (Diluted) -1,12 -1,27 -1,67 -1,98 -1,61
Gross Profit 0,0 0,0 0,0 1,00M 0,0
Operating Income -101,87M -102,56M -62,03M -49,86M -37,03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 363,93M 268,52M 287,03M 168,07M 92,29M
Total Liabilities 18,06M 13,15M 10,08M 7,77M 23,70M
Shareholders' Equity 345,87M 255,37M 276,94M 160,30M 68,59M
Total Debt 1,35M 603.000,0 1,21M 0,0 12,88M
Cash & Equivalents 161,44M 79,93M 143,24M 47,70M 74,85M
Current Assets 362,11M 267,43M 285,19M 166,93M 90,87M
Current Liabilities 15,65M 11,94M 8,47M 6,82M 22,82M